Methods and nucleic acid molecules for aav vector selection
US-2024417717-A1 · Dec 19, 2024 · US
AAV's and uses thereof
US9284357B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9284357-B2 |
| Application number | US-201414246560-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 7, 2014 |
| Priority date | May 28, 2009 |
| Publication date | Mar 15, 2016 |
| Grant date | Mar 15, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention in some aspects relates to recombinant adeno-associated viruses having distinct tissue targeting capabilities. In some aspects, the invention relates to gene transfer methods using the recombinant adeno-associate viruses. In some aspects, the invention relates to isolated AAV capsid proteins and isolated nucleic acids encoding the same.
First claim
Opening claim text (preview).
What is claimed is: 1. A composition comprising an isolated adeno-associated virus (AAV) vector wherein the isolated adeno-associated virus (AAV) vector comprises (i) the isolated adeno-associated virus (AAV) capsid protein of the amino acid sequence SEQ ID NO: 91; and (ii) a nucleic acid encoding a heterologous transgene. 2. The composition of claim 1 , further comprising a pharmaceutically acceptable carrier. 3. The composition of claim 1 , wherein the heterologous transgene comprises a tissue-specific promoter operably linked to a coding sequence. 4. The composition of claim 3 , wherein the coding sequence encodes a therapeutic protein. 5. The composition of claim 4 , wherein the therapeutic protein is aromatic amino acid decarboxylase (AADC).
Assignees
Inventors
Classifications
Drugs for disorders of the cardiovascular system · CPC title
Drugs for disorders of the nervous system · CPC title
Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy · CPC title
Drugs for disorders of the respiratory system · CPC title
Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9284357B2 cover?
- The invention in some aspects relates to recombinant adeno-associated viruses having distinct tissue targeting capabilities. In some aspects, the invention relates to gene transfer methods using the recombinant adeno-associate viruses. In some aspects, the invention relates to isolated AAV capsid proteins and isolated nucleic acids encoding the same.
- Who is the assignee on this patent?
- Univ Massachusetts
- What technology area does this patent fall under?
- Primary CPC classification C07K14/005. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 15 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).